IQVIA (NYSE: IQV) Releases Fiscal 2021 Profit Guidance
IQVIA (NYSE: IQV) on Tuesday morning released an update of its earnings guidance for fiscal 2021. The company provided earnings per share (EPS) guidance of $ 8,700 to $ 8,900 for the period, compared Thomson Reuters consensus estimate of $ 8.690. The company released a revenue forecast of $ 13.55 billion to $ 13.70 billion, compared to the consensus revenue estimate of $ 13.44 billion. IQVIA also updated its forecast for the third quarter of 2021 to $ 2.060 to $ 2.130 per share.
NYSE IQV shares opened at $ 247.30 on Tuesday. The stock has a fifty-day moving average price of $ 243.94. The company has a current ratio of 1.05, a quick ratio of 1.05, and a debt ratio of 2.11. The stock has a market cap of $ 47.39 billion, a PE ratio of 79.26, a PEG ratio of 2.34 and a beta of 1.42. IQVIA has a one-year minimum of $ 146.00 and a one-year maximum of $ 254.05.
IQVIA (NYSE: IQV) last reported its quarterly results on Tuesday, July 27. The medical research company reported earnings per share (EPS) of $ 2.13 for the quarter, beating Zacks’ consensus estimate of $ 2.07 by $ 0.06. The company posted revenue of $ 3.44 billion in the quarter, compared to $ 3.27 billion expected by analysts. IQVIA had a net margin of 4.69% and a return on equity of 23.95%. The company’s revenue for the quarter increased 36.4% from the same quarter last year. During the same period of the previous year, the company posted earnings per share of $ 1.18. On average, sell-side analysts expect IQVIA to post earnings per share of 8.24 for the current fiscal year.
IQV has been the subject of several research reports. Citigroup raised its target price on IQVIA shares from $ 265.00 to $ 280.00 and gave the stock a buy rating in a research report on Wednesday, July 28. Truist raised its target price on IQVIA shares from $ 235.00 to $ 260.00 in a research report on Monday, April 26. Credit Suisse Group raised its target price on IQVIA shares from $ 242.00 to $ 265.00 and gave the stock an outperformance rating in a research report published on Tuesday, July 20. Piper Sandler raised her target price on IQVIA shares from $ 204.00 to $ 235.00 and gave the stock a neutral rating in a research report published on Wednesday, July 28. Finally, they raised their target price on IQVIA shares from $ 225.00 to $ 265.00 in a research report on Friday, April 23. Two equity research analysts rated the stock with a conservation rating and fifteen gave the company a buy rating. The stock currently has a buy consensus rating and an average price target of $ 255.53.
IQVIA Holdings Inc provides advanced analytics, technology solutions and clinical research services to the life sciences industry in the Americas, Europe, Africa and Asia-Pacific. It operates through three segments: Technology and Analytical Solutions, Research and Development Solutions, and Contract Sales, and Medical Solutions.
Further Reading: The Basic Economy Creates Winners and Losers
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in IQVIA now?
Before you consider IQVIA, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the market in general takes hold … and IQVIA was not on the list.
Although IQVIA currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here